EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Win Ratio Analysis of Transvenous Phrenic Nerve Stimulation to Treat Central Sleep Apnoea in Heart Failure

William T Abraham, Olaf Oldenburg, Mitja Lainscak, Rami Khayat, Jerryll Asin, Piotr Ponikowski, Robin Germany, Scott McKane, Maria Rosa Costanzo

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15074 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von William T Abraham und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine and the Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, Ohio, U…. Hauptthemen laut MEDLINE: Phrenic Nerve, Sleep Apnea, Central, Heart Failure, Electric Stimulation Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZOLL Respicardia, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Central sleep apnoea (CSA) is present in 20–40% of heart failure (HF) patients and is associated with poor clinical outcomes and health status. Transvenous phrenic nerve stimulation (TPNS) is an available treatment for CSA in HF patients. The impact on HF outcomes is incompletely understood. The win ratio (WR) allows inclusion of multiple endpoint components, considers the relative severity of each component, and permits assessment of recurrent events in evaluation of clinical benefit. Methods and results A WR hierarchy was pre-defined for analysis of the HF subgroup of the remedē® System Pivotal Trial. The analysis used three hierarchical components to compare all treated to all control subjects: longest survival, lowest HF hospitalization rate, and ≥2-category difference in Patient Global Assessment at 6 months. Sensitivity analyses were performed substituting Epworth Sleepiness Scale and 4% oxygen desaturation index for the third component, and a 4-component WR hierarchy was also evaluated. Ninety-one HF subjects, 43 receiving TPNS and 48 in the control group, provided 2064 pairwise comparisons. More patients treated with TPNS experienced clinical benefit compared with control (WR 4.92, 95% confidence interval 2.27–10.63, P < 0.0001). There were 1111 (53.83%) winning pairwise comparisons for the treatment group and 226 (10.95%) for the control group. Similarly, large WRs were observed for all additional WR hierarchies.

Conclusions

This WR analysis of the remedē® System Pivotal Trial suggests that TPNS may be superior to untreated CSA in HF patients with CSA using a hierarchical clinical benefit endpoint composed of mortality, HF hospitalization, and health status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phrenic NerveSleep Apnea, CentralHeart FailureElectric Stimulation TherapyHumansMaleFemaleMiddle AgedTreatment OutcomeAgedFollow-Up StudiesPolysomnography

Stichwörter der Autor:innen

Central sleep apnoeaHeart failureTransvenous phrenic nerve stimulationWin ratio

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine and the Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Department of Cardiology, Ludgerus-Kliniken, Münster, Germany.
  • Faculty of Medicine, University of Ljubljana, Division of Cardiology, General Hospital Murska Sobota, Ljubljana, Slovenia.
  • Division of Pulmonary and Critical Care Medicine and the UCI Sleep Disorders Center, University of California Irvine, Irvine, California, USA.
  • Department of Pulmonary Diseases and Center for Sleep Medicine, Amphia Ziekenhuis, Breda, Netherlands.
  • Institute of Heart Diseases, University Hospital of Wroclaw Medical University, Wroclaw, Poland.

Förderung

  • ZOLL Respicardia, Inc

Zitieren

APA

Abraham, W. T., Oldenburg, O., Lainscak, M., Khayat, R., Asin, J., Ponikowski, P., Germany, R., McKane, S., & Costanzo, M. R. (2025). Win Ratio Analysis of Transvenous Phrenic Nerve Stimulation to Treat Central Sleep Apnoea in Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.15074

Vancouver

Abraham WT, Oldenburg O, Lainscak M, Khayat R, Asin J, Ponikowski P, et al. Win Ratio Analysis of Transvenous Phrenic Nerve Stimulation to Treat Central Sleep Apnoea in Heart Failure. ESC Heart Failure. 2025. doi:10.1002/ehf2.15074

BibTeX
@article{Abraham2025,
  author = {Abraham, William T and Oldenburg, Olaf and Lainscak, Mitja and Khayat, Rami and Asin, Jerryll and Ponikowski, Piotr and Germany, Robin and McKane, Scott and Costanzo, Maria Rosa},
  title = {Win Ratio Analysis of Transvenous Phrenic Nerve Stimulation to Treat Central Sleep Apnoea in Heart Failure},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15074}
}
Kostenlos starten →